Key PointsFoundayo (orforglipron) has a serious advantage over Novo Nordisk's Wegovy pill.
Loading story…
4 views
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight
Key PointsFoundayo (orforglipron) has a serious advantage over Novo Nordisk's Wegovy pill.
More in Markets
Same desk, different stories
- Markets
A Photronics Director Sold 10,000 Company Shares. Should Investors Avoid the Stock?
Key PointsDirector Mitchell Tyson sold 10,000 shares of Common Stock on April 1, 2026 for a transaction value of ~$423,000 based on a weighted average sale price around $42.31 per share.
- Markets
If You'd Invested $100 in CVS Health (CVS) Stock 5 Years Ago, Here's How Much You'd Have Today (Spoiler: You Wouldn't Have Lost Money)
Key PointsCVS Health is facing some headwinds, which have adversely affected its stock price.
- Markets
Brookfield Corporation Has Become the Next Berkshire Hathaway
Key PointsBrookfield Corporation is a large and well-respected Canadian investment company.
- Markets
Billionaire Philippe Laffont Sold CoreWeave and Bought This Artificial Intelligence (AI) Stock Instead
Key PointsCoreWeave is growing quickly, but it's highly leveraged.
- Markets
Why ExxonMobil Stock Soared More Than 11% in March
Key PointsThe war with Iran fueled a surge in crude prices, benefiting oil stocks.
- Markets
TSMC vs. Nvidia: Which AI Supercycle Growth Stock Is the Better Long-Term Buy?
Key PointsNvidia's future continues to look bright as it continues to evolve.